CJC-1295 with DAC vs Dianabol
Well Studied vs Well Studied
synergistic Mechanism-based · 60% Dianabol helps manage estrogen conversion from CJC-1295 with DAC. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
CJC-1295 with DAC Dianabol
Weight 3,647.28 Da 300.44 Da
Half-life 6-8 days ~4-6 hours
Chain 30 amino acids —
Type GHRH analog with DAC 17-alpha-alkylated anabolic steroid (C20H28O2)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Dianabol
20-50 mg/day / Split doses throughout the day
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Research Evidence
CJC-1295 with DAC Dianabol
Status Well Studied Well Studied
References 4 studies 5 studies
Latest 2025 2017
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.